Document is current
Any future updates will be listed below
-
Authors
Costa, Enrico https://orcid.org/0000-0003-2616-994X
Girotti, Silvia
Pauro, Francesca
Leufkens, Hubert G. M.
Cipolli, Marco
- License Information
-
More Information
Article History
Received: 10 February 2022
Accepted: 26 April 2022
First Online: 7 May 2022
Declarations
:
: Not applicable.
: Not applicable.
: EC: member of the Committee for Orphan Medicinal Products (COMP) at EMA. The views expressed in this article are the personal views of the author and may not be understood or quoted as being made on behalf of or reflecting the position of the regulatory agency with which the author is affiliated. SG: the author declares that she has no competing interests. FP: the author declares that she has no competing interests. HL: former chair of the Dutch Medicines Evaluation Board (MEB), former member of several committees and working parties of the European Medicines Agency (EMA). MC: received grants from Vertex Ph (ISS), from the Italian Minister of Health (COVID-2020-12371781) and from Pfizer (ID_61509709). He also served on advisory boards for Vertex Ph, Chiesi, Viatris, Kither.
